Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-958 biodistribution in healthy subjects
NCT03472313Phase 1Completed
- Sponsor
- Invicro
- Start
- Nov 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florzolotau in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), sponsored by Invicro. Primary endpoints: Assessment of the Biodistribution of [18F]MNI-958 at 2 months, Assessment of Safety of [18F]MNI-958 at 2 months and 1 more. Started Nov 2017; status: completed.
02
Drugs
florzolotau
03
Conditions
Alzheimer's disease (AD)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03472313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472313.